Treatment of Overactive Urinary Bladder with Oxybutinin Improves Quality of Life and Urodynamic Parameters in Multiple Sclerosis

Abstract

Background. The most common voiding disturbance in patients with multiple sclerosis is a spastic bladder or overactive bladder.

Aim. To evaluate the efficiency of the therapy with oxybutinin on urodynamic parameters and the quality of life of patients with an overactive bladder in multiple sclerosis.

Patients and Methods.  This was the cross-over study that tested the efficiency of oxybutinin tablets prescribed in a daily dose of 2x5 mg. Urodynamic testing and the quality of life questionnaires were filled out before and after the treatment with oxybutinin for 3 months. Urodynamic parameters included the first detrusor contraction, maximum capacity,  number of daily and night micturition, and the number of daily and night  incontinence.

Results. There were 30 patients enrolled. Questionnaires' scores of symptoms before and after treatment were 62 ±15 and 32±15, respectively (< 0,0001). Questionnaires' scores of quality of life before and after treatment were 28±14 and 56±15, respectively (< 0,0001). The first detrusor contraction improved from 79,6±43,7 ml to 131±62,7 (p<0,0001), maximal capacity from 223,2±68,9, to 317,3±101,1 ml (p<0,0001). Daily micturition number decreased from 13,3±4,7 to 7,05±2,2 (p<0,0001), night micturition number from 3,5 to 2 (p<0,0001). Daily incontinence number decreased from 2,6±1,9 to 1,1±1,2(p<0,0001), night incontinence number  from 1 to 0 (p=0,0002). The side effects of the therapy were found in 35% of patients as dryness in the mouth, which did not require interruption of therapy.

Conclusion. Our results showed that the treatment of an overactive bladder with Oxybutinin of 2x5 mg. doses, improved the quality of life and urodynamic parameters in patients with multiple sclerosis.

Keywords.  Multiple sclerosis – Oxybutinin- Over active bladder